1. Search Result
Search Result
Isoforms Recommended: Nav1.8
Results for "

Na(V)1.8

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

3

Peptides

1

Natural
Products

1

Recombinant Proteins

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155635

    Sodium Channel Infection
    Nav1.8-IN-4 (compound 9a) is a Nav1.8 channel inhibitor (IC50=0.014 μM). Nav1.8-IN-4 can be used for research on pain-related diseases .
    Nav1.8-IN-4
  • HY-132133

    Sodium Channel Neurological Disease Inflammation/Immunology
    Nav1.8-IN-1 (Compound 31) is a potent inhibitor of Na(v)1.8 sodium channel. Nav1.8-IN-1 has the potential for the research of inflammatory and neuropathic pain .
    Nav1.8-IN-1
  • HY-161272

    Sodium Channel Neurological Disease
    Nav1.8-IN-6 (Compound 2j) is a novel pyridinone amide Nav1.8 channel inhibitor. The IC50 values in the resting state and semi-activated state are 513.33 and 471.81 nM, respectively. Nav1.8-IN-6 has analgesic activity .
    Nav1.8-IN-6
  • HY-160591

    Sodium Channel Neurological Disease
    Nav1.8-IN-10 (Compound 6) is a Nav1.8 channel inhibitor. When the concentration is 4 nM, the percentage blocking rate of Nav1.8 channel is 79.4%. Nav1.8-IN-10 can be used in the study of pain disorders .
    Nav1.8-IN-10
  • HY-160588

    Sodium Channel Potassium Channel Neurological Disease
    Nav1.8-IN-7 (Example 116) is a selective Nav1.8 inhibitor. Nav1.8-IN-7 shows an inhibition of >50% with 100 nM for Nav1.8. Nav1.8-IN-7 inhibits hERG with an IC50 of 15.6 μM. Nav1.8-IN-7 has the potential for pain research .
    Nav1.8-IN-7
  • HY-161572

    Sodium Channel Cardiovascular Disease
    Nav1.8-IN-13 (compound 16) is a Nav1.8 inhibitor (pIC50=7.9) .
    Nav1.8-IN-13
  • HY-160593

    Sodium Channel Neurological Disease
    Nav1.8-IN-12 (Compound 23 R) is a Nav1.8 channel inhibitor. Nav1.8-IN-12 can be used in the study of pain-related diseases .
    Nav1.8-IN-12
  • HY-158979

    Sodium Channel Neurological Disease
    Nav1.8-IN-14 (compound 20) is a potent and selective Nav1.8 inhibitor. Nav1.8-IN-14 can be used in the study of pain-related diseases .
    Nav1.8-IN-14
  • HY-160592

    Sodium Channel Neurological Disease
    Nav1.8-IN-11 (Example 1) is a Nav1.8 channel inhibitor with a IC50 value of 0.1 nM. Nav1.8-IN-11 can be used in the study of pain disorders .
    Nav1.8-IN-11
  • HY-160589

    Sodium Channel Neurological Disease
    Nav1.8-IN-8 (Compound A11) is a Nav1.8 channel inhibitor. Nav1.8-IN-8 may prevent associated diseases mediated by sodium ion channels (NaV) .
    Nav1.8-IN-8
  • HY-159094

    Sodium Channel Neurological Disease
    Nav1.8-IN-15 (compound 6) is a potent Nav1.8 inhibitor. Nav1.8-IN-15 shows analgesic effect. Nav1.8-IN-15 has the potential for the research of chronic pain .
    Nav1.8-IN-15
  • HY-143481

    Sodium Channel Neurological Disease
    Nav1.8-IN-2 (compound 35A) is a potent Nav1.8 inhibitor with an IC50 value of 0.4 nM. Nav1.8-IN-2 can be used for researching pain disorders, cough disorders, and acute and chronic itch disorders .
    Nav1.8-IN-2
  • HY-162246

    Sodium Channel Cardiovascular Disease Neurological Disease
    Nav1.8-IN-5 (Example 1) is a voltage-gated sodium channel Nav1.8 inhibitor. Nav1.8-IN-5 can be used for Nav1.8-mediated diseases, such as pain and pain-related disorders, as well as cardiovascular diseases (such as atrial fibrillation) research .
    Nav1.8-IN-5
  • HY-100080

    Sodium Channel Neurological Disease
    A-887826 is a potent, selective, oral bioavailable and voltage-dependent Na(v)1.8 sodium channel blocker with an IC50 of 11 nM . A-887826 attenuates neuropathic tactile allodynia in vivo .
    A-887826
  • HY-101383
    PF-01247324
    1 Publications Verification

    Sodium Channel Neurological Disease
    PF-01247324 is a selective and orally bioavailable Nav1.8 channel blocker with an IC50 of 196 nM for recombinant human Nav1.8 channel.
    PF-01247324
  • HY-149944

    Sodium Channel Inflammation/Immunology
    Analgesic agent-2 is a selective and orally active NaV1.8 Channel inhibitor, with an IC50 of 50.18 nM in HEK293 cells stably expressing human NaV1.8 channel. Analgesic agent-2 has analgesic activity .
    Analgesic agent-2
  • HY-163855

    Sodium Channel GABA Receptor Neurological Disease
    KGP-25 is an inhibitor of voltage-gated sodium channel 1.8 (Nav1.8), which can be used for analgesia by targeting Nav1.8 in the peripheral nervous system (PNS). KGP-25 can also target γ-aminobutyric acid subtype A receptor (GABAA) in the central nervous system (CNS) for general anesthesia .
    KGP-25
  • HY-157802

    Sodium Channel Neurological Disease
    LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research .
    LTGO-33
  • HY-139346

    Sodium Channel Neurological Disease
    VX-150 is an orally active, highly selective NaV1.8 inhibitor. VX-150 has the potential for various pain indications research .
    VX-150
  • HY-114301

    Sodium Channel Neurological Disease
    PF-06305591 is a potent and highly selective voltage gated sodium channel NaV1.8 blocker, with an IC50 of 15 nM. An excellent preclinical in vitro ADME and safety profile .
    PF-06305591
  • HY-110325

    Sodium Channel Neurological Disease
    PF-04885614 is a potent NaV1.8 inhibitor, extracted from patent US2018328915. PF-04885614 has potential for neurological and neurodevelopmental diseases treatment .
    PF-04885614
  • HY-157802A

    Sodium Channel Neurological Disease
    (S)-LTGO-33 is a small molecule inhibitor of voltage-gated sodium channel NaV1.8. (S)-LTGO-33 can be used in the treatment of pain disorders .
    (S)-LTGO-33
  • HY-114301A

    Sodium Channel Neurological Disease
    PF-06305591 dihydrate is a potent and highly selective voltage gated sodium channel NaV1.8 blocker, with an IC50 of 15 nM. An excellent preclinical in vitro ADME and safety profile .
    PF-06305591 dihydrate
  • HY-160903

    Sodium Channel Neurological Disease
    Suzetrigine phenol is the phenolate form of the sodium channel modulator Suzetrigine (HY-148800). Suzetrigine (VX-548) is an orally active and highly selective inhibitor of NaV1.8 .
    Suzetrigine phenol
  • HY-B1837

    Sodium Channel Infection
    Cyfluthrin is a type II pyrethroid and has effects on various insects. Cyfluthrin is a modulator of Nav1.8 sodium channels by repetitive stimulation. Cyfluthrin can be applied in agriculture,veterinary, insecticide,pyrethroid and stored product .
    Cyfluthrin
  • HY-16723

    TV 45070; XEN402

    Sodium Channel Neurological Disease Inflammation/Immunology
    Funapide (TV 45070; XEN402) is a potent inhibitor of the sodium channel Nav1.7, Nav1.8 and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent .
    Funapide
  • HY-16723A

    (R)-TV 45070; (R)-XEN402

    Sodium Channel Neurological Disease Inflammation/Immunology
    (R)-Funapide ((R)-TV 45070) is the less active R-enantiomer of Funapide. Funapide is a potent inhibitor of the sodium channel Nav1.7, Nav1.8 and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent .
    (R)-Funapide
  • HY-105283

    Sodium Channel Others Neurological Disease
    PF 04531083 is an orally active and selective NaV1.8 blocker with an IC50 of 0.7 μM. PF 04531083 is a blood-brain barrier (BBB) penetrant compound. PF 04531083 can be used for the research of respiratory system and neuropathic/inflammatory pain .
    PF 04531083
  • HY-P5786

    Potassium Channel Sodium Channel Neurological Disease
    Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits Nav1.7 and activates Nav1.9 but does not affect Nav1.8 .
    Heteropodatoxin-1
  • HY-148800
    Suzetrigine
    1 Publications Verification

    VX-548

    Sodium Channel Neurological Disease
    Suzetrigine (VX-548) is an orally active and highly selective NaV1.8 inhibitor that acts as an analgesic. Suzetrigine is also a blocker of sodium channel protein type 10 subunit alpha. Suzetrigine is promising for research of acute pain after abdominoplasty and bunionectomy .
    Suzetrigine
  • HY-146069

    Sodium Channel Neurological Disease
    ABBV-318 is a potent Nav1.7/ Nav1.8 blocker, with IC50s of 2.8 μM and 3.8 μM for hNav1.7 and hNav1.8, respectively. ABBV-318 can be used for the research of pain .
    ABBV-318
  • HY-N1847

    Sodium Channel Neurological Disease
    3'-Methoxydaidzein is a isoflavone and a Sodium Channel inhibitor. 3'-Methoxydaidzein inhibits subtypes NaV1.7, NaV1.8 and NaV1.3 with IC50 of 181 nM, 397 nM, and 505 nM, respectively. 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels .
    3'-Methoxydaidzein
  • HY-B1837S

    β-Cyfluthi-d6

    Isotope-Labeled Compounds Sodium Channel Infection
    Cyfluthrin-d6 (β-Cyfluthi-d6) is deuterium labeled Cyfluthrin. Cyfluthrin is a type II pyrethroid and has effects on various insects. Cyfluthrin is a modulator of Nav1.8 sodium channels by repetitive stimulation. Cyfluthrin can be applied in agriculture,veterinary, insecticide,pyrethroid and stored product .
    Cyfluthrin-d6
  • HY-P5916

    κ-Theraphotoxin-Gr4a; Kappa-TRTX-Gr4a; Voltage sensor toxin 3; Peptide F

    Others Potassium Channel Neurological Disease
    VSTx-3 is a KV channel blocker. VSTx-3 is demonstrated to be a potent, TTX-sensitive sodium channel blocker and especially, a potent blocker of NaV1.8 channels (IC50 0.19 μM for hNaV1.3, 0.43 μM for hNaV1.7 and 0.77 μM for hNaV1.8 channels).
    VSTx-3
  • HY-11079
    A-803467
    2 Publications Verification

    Sodium Channel Neurological Disease Inflammation/Immunology Cancer
    A-803467 is a potent and selective tetrodotoxin-resistant Nav1.8 sodium channel blocker (IC50=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter .
    A-803467
  • HY-B0824
    Bifenthrin
    1 Publications Verification

    Sodium Channel Neurological Disease
    Bifenthrin is a synthetic pyrethroid insecticide. Bifenthrin prolongs the opening time of Nav1.8 sodium channels, leading to membrane depolarization and conductance block in the insect nervous system, thereby disrupting neural function. Bifenthrin was effective in inhibiting A. gambiae (LD50=0.15 ng/mg) and C. quinquefasciatus (LD50=0.16 ng/mg). Bifenthrin has good lethality against susceptible and resistant mosquitoes and is very effective in inhibiting blood sucking and can be developed as a mosquito-removal netting material .
    Bifenthrin
  • HY-B0824R

    Sodium Channel Neurological Disease
    Bifenthrin (Standard) is the analytical standard of Bifenthrin. This product is intended for research and analytical applications. Bifenthrin is a synthetic pyrethroid insecticide. Bifenthrin prolongs the opening time of Nav1.8 sodium channels, leading to membrane depolarization and conductance block in the insect nervous system, thereby disrupting neural function. Bifenthrin was effective in inhibiting A. gambiae (LD50=0.15 ng/mg) and C. quinquefasciatus (LD50=0.16 ng/mg). Bifenthrin has good lethality against susceptible and resistant mosquitoes and is very effective in inhibiting blood sucking and can be developed as a mosquito-removal netting material .
    Bifenthrin (Standard)
  • HY-16787
    ICA-121431
    2 Publications Verification

    Sodium Channel Cardiovascular Disease
    ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Nav) blocker, shows equipotent selectivity for human Nav1.1 and Nav1.3 subtypes with IC50 values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Nav1.2 (IC50=240 nM) and 1,000 fold selectivity against Nav1.4, Nav1.6, and the TTX-resistant human Nav1.5 and Nav1.8 channels (IC50s >10 μM).
    ICA-121431
  • HY-P1441A

    Sodium Channel Neurological Disease
    Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC50 values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.
    Mambalgin 1 TFA